30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Pluristem to Conduct Phase III Trial of PLX-PAD Following Hip Fracture Surgery -

Pluristem Therapeutics intends to conduct a U.S./EU Phase III trial assessing use of PLX-PAD (PLacental eXpanded) cells to support recovery following surgery for femoral neck fracture.

The study design builds upon positive data from the Phase II trial which showed that PLX-PAD cells induced significant muscle regeneration following total hip replacement. Compared to placebo, patients treated with PLX-PAD at the time of surgery showed a 500% improvement in muscle force and a 300% improvement in muscle volume at 6 months.

Earlier results from the Phase I/II study were announced in 1Q15.

Sources: Plurstem Therapeutics, Inc.; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.